Haleon (HLN) Net Income towards Common Stockholders (2021 - 2023)
Haleon (HLN) posted Net Income towards Common Stockholders of $852.7 million for Q4 2023, up 128.66% on a QoQ basis from $372.9 million in Q2 2023, and down 15.67% year-over-year from $1.0 billion in Q4 2022.
Haleon (HLN) Net Income towards Common Stockholders (2021 - 2023) Analysis & Trends
Haleon's Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at $852.7 million for Q4 2023.
- Quarterly Net Income towards Common Stockholders fell 15.67% year-over-year to $852.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2025 was $852.7 million (down 30.43% YoY) and the FY2025 annual result came in at $2.2 billion, up 19.24% from the prior year.
- Net Income towards Common Stockholders was $852.7 million for Q4 2023 at Haleon, up from $372.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.2 billion in Q4 2021 and bottomed at $372.9 million in Q2 2023.
- A 3-year average of $751.8 million and a median of $744.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slipped 12.99% — and 2023, when it retreated 15.67%.
- Haleon's Net Income towards Common Stockholders stood at $1.2 billion in 2021, then slipped by 12.99% to $1.0 billion in 2022, then declined by 15.67% to $852.7 million in 2023.
- Business Quant data shows HLN's Net Income towards Common Stockholders at $852.7 million in Q4 2023, $372.9 million in Q2 2023, and $475.7 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 852.67 Mn |
| Jun 30, 2023 | 372.91 Mn |
| May 3, 2023 | 475.66 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 20, 2022 | 636.58 Mn |
| Dec 31, 2021 | 1.16 Bn |